136:
198:
66:
25:
421:
budget, an equivalent amounts from Member States' activities, and the remaining €200 million from industry, charities, and private organisations. The
Partnership is intended to be a long-term initiative (10–20 years) and a separate legal entity has been created to maintain its independence and
38:
425:
Taken together, clinical trials based in developing countries where the diseases are endemic, capacity building, and South-South networking are expected to make up over 90% of the overall budget. (figure).
305:, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries.
387:
Acceleration of the development of new or improved drugs, vaccines and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa.
330:
The
Programme was to be based on three central pillars: "the impact of existing interventions, the affordability of key pharmaceuticals and trade, and the research and development of specific
564:
408:
699:
44:
621:
371:
Partnerships among EU and developing countries that focuses specifically on developing countries' needs, who are jointly involved in setting the research priorities.
689:
395:
Manifested as a general strengthening of clinical research capacity in Africa, including training activities, workshops and meetings, and the upgrading of
99:
486:
694:
584:
91:
417:
The total budget of the EDCTP is €600 million for the period 2003–2007, of which one third (€200 million) is to be provided by the
523:
363:
and associated countries, allowing focused collaboration of national and
European efforts that were not previously coordinated.
578:
379:
Efforts aimed at creating lasting long-term partnerships between
African scientists and research institutions in Africa.
76:
574:
233:
179:
157:
117:
52:
150:
317:
293:
The need for global action against these diseases in order to promote poverty reduction has been recognised by the
314:
Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction
85:
568:
328:
588:
594:
648:
412:
335:
598:
684:
627:
518:
514:
342:
291:
144:
95:
267:
81:
161:
8:
579:
https://web.archive.org/web/20121012112446/http://www.gatesfoundation.org/Pages/home.aspx
338:
324:
320:
211:
Please help update this article to reflect recent events or newly available information.
331:
309:
481:
396:
271:
411:
Proposed EDCTP expenditure for the first five years of the
Programme (2003-2007)
604:
501:
496:
445:
418:
360:
294:
255:
678:
569:
https://web.archive.org/web/20090318151237/http://www.aeras.org/home/home.php
407:
323:. The Commission proposal was adopted on 16 June 2003 by the Council and the
302:
589:
https://web.archive.org/web/20071008192438/http://www.ipm-microbicides.org/
491:
283:
547:
453:
263:
599:
https://web.archive.org/web/20090214212631/http://www.mmv.org/index.php
65:
287:
275:
449:
438:
337:
These aims relate specifically with the EU stance on access to
259:
669:
European and
Developing Countries Clinical Trials Partnership
476:
248:
European and
Developing Countries Clinical Trials Partnership
608:
551:
622:
541:
266:
and developing countries and other donors, as well as the
700:
Medical and health organisations based in the
Netherlands
668:
279:
298:
534:
527:
676:
80:, potentially preventing the article from being
649:"Research and innovation - European Commission"
690:International medical and health organizations
533:International Aids Vaccine Initiative (IAVI) (
319:) on 15 May 2001, following its launch by the
429:
53:Learn how and when to remove these messages
585:International Partnership for Microbicides
346:
100:reliable, independent, third-party sources
274:and the development of new medicines and
234:Learn how and when to remove this message
180:Learn how and when to remove this message
118:Learn how and when to remove this message
406:
375:South/South networking and co-ordination
367:North/South networking and co-ordination
355:North/North networking and co-ordination
143:This article includes a list of general
94:by replacing them with more appropriate
524:Drugs for Neglected Diseases initiative
515:The World Health Organization (WHO-TDR)
77:too closely associated with the subject
677:
351:EDCTP-funded activities are based on:
695:National agencies for drug regulation
575:The Bill and Melinda Gates Foundation
191:
129:
59:
18:
540:European Vaccine Initiative (EVI) (
383:Supporting relevant clinical trials
13:
565:Aeras Global TB Vaccine Foundation
466:All sub-Saharan African countries.
149:it lacks sufficient corresponding
14:
711:
662:
34:This article has multiple issues.
559:Private non-profit organisations
196:
134:
75:may rely excessively on sources
64:
23:
254:) is a partnership between the
42:or discuss these issues on the
641:
1:
634:
595:Medicines for Malaria Venture
7:
615:
10:
716:
430:Member states and partners
402:
628:European Medicines Agency
609:http://www.wellcome.ac.uk
552:http://www.tballiance.org
509:International initiatives
205:This article needs to be
542:http://www.euvaccine.eu
471:Industry and commercial
359:Partnerships among the
347:Projects and activities
268:pharmaceutical industry
164:more precise citations.
414:
410:
461:Developing countries
448:member states, plus
535:http://www.iavi.org
528:http://www.dndi.org
339:essential medicines
332:global public goods
325:European Parliament
321:European Commission
605:The Wellcome Trust
415:
685:Clinical research
399:sites in Africa.
391:Capacity building
244:
243:
236:
226:
225:
190:
189:
182:
128:
127:
120:
57:
707:
656:
655:
653:
645:
434:Are as follows:
310:European Council
239:
232:
221:
218:
212:
200:
199:
192:
185:
178:
174:
171:
165:
160:this article by
151:inline citations
138:
137:
130:
123:
116:
112:
109:
103:
68:
60:
49:
27:
26:
19:
715:
714:
710:
709:
708:
706:
705:
704:
675:
674:
665:
660:
659:
651:
647:
646:
642:
637:
618:
487:Novartis Pharma
482:GlaxoSmithKline
432:
405:
349:
316:(COM (2001)96,
272:clinical trials
240:
229:
228:
227:
222:
216:
213:
210:
201:
197:
186:
175:
169:
166:
156:Please help to
155:
139:
135:
124:
113:
107:
104:
89:
69:
28:
24:
17:
12:
11:
5:
713:
703:
702:
697:
692:
687:
673:
672:
664:
663:External links
661:
658:
657:
639:
638:
636:
633:
632:
631:
625:
617:
614:
613:
612:
602:
592:
582:
572:
561:
560:
556:
555:
545:
538:
531:
521:
511:
510:
506:
505:
502:Sanofi-Aventis
499:
497:Sanofi Pasteur
494:
489:
484:
479:
473:
472:
468:
467:
463:
462:
458:
457:
442:
441:
431:
428:
404:
401:
397:clinical trial
393:
392:
385:
384:
377:
376:
369:
368:
357:
356:
348:
345:
295:United Nations
256:European Union
242:
241:
224:
223:
204:
202:
195:
188:
187:
142:
140:
133:
126:
125:
72:
70:
63:
58:
32:
31:
29:
22:
15:
9:
6:
4:
3:
2:
712:
701:
698:
696:
693:
691:
688:
686:
683:
682:
680:
670:
667:
666:
650:
644:
640:
629:
626:
623:
620:
619:
610:
606:
603:
600:
596:
593:
590:
586:
583:
580:
576:
573:
570:
566:
563:
562:
558:
557:
553:
549:
546:
543:
539:
536:
532:
529:
525:
522:
519:
516:
513:
512:
508:
507:
503:
500:
498:
495:
493:
490:
488:
485:
483:
480:
478:
475:
474:
470:
469:
465:
464:
460:
459:
455:
451:
447:
444:
443:
440:
437:
436:
435:
427:
423:
422:flexibility.
420:
413:
409:
400:
398:
390:
389:
388:
382:
381:
380:
374:
373:
372:
366:
365:
364:
362:
354:
353:
352:
344:
343:
340:
336:
333:
329:
326:
322:
318:
315:
311:
306:
304:
303:African Union
300:
296:
292:
289:
285:
281:
277:
273:
269:
265:
261:
257:
253:
249:
238:
235:
220:
208:
203:
194:
193:
184:
181:
173:
170:February 2021
163:
159:
153:
152:
146:
141:
132:
131:
122:
119:
111:
108:February 2013
101:
97:
93:
87:
83:
79:
78:
73:This article
71:
67:
62:
61:
56:
54:
47:
46:
41:
40:
35:
30:
21:
20:
643:
492:Novo Nordisk
433:
424:
416:
394:
386:
378:
370:
358:
350:
313:
312:adopted the
307:
284:tuberculosis
270:, to enable
251:
247:
245:
230:
214:
206:
176:
167:
148:
114:
105:
90:Please help
74:
50:
43:
37:
36:Please help
33:
548:TB Alliance
454:Switzerland
264:Switzerland
162:introducing
16:Partnership
679:Categories
635:References
301:, and the
217:April 2021
145:references
92:improve it
82:verifiable
39:improve it
96:citations
45:talk page
616:See also
280:HIV/AIDS
278:against
276:vaccines
671:(EDCTP)
624:(EORTC)
403:Funding
288:malaria
207:updated
158:improve
86:neutral
630:(EMEA)
450:Norway
439:Europe
297:, the
286:, and
260:Norway
258:(EU),
147:, but
652:(PDF)
477:Bayer
252:EDCTP
452:and
308:The
246:The
84:and
98:to
681::
446:EU
419:EU
361:EU
341:.
334:."
299:G8
282:,
262:,
48:.
654:.
611:)
607:(
601:)
597:(
591:)
587:(
581:)
577:(
571:)
567:(
554:)
550:(
544:)
537:)
530:)
526:(
520:)
517:(
504:.
456:.
327:.
290:.
250:(
237:)
231:(
219:)
215:(
209:.
183:)
177:(
172:)
168:(
154:.
121:)
115:(
110:)
106:(
102:.
88:.
55:)
51:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
